Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions-Reference-Cited by-同舟云学术

Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions

Published:2021-07-21 Issue:15 Volume:64 Page:10621-10640
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Shiyan¹²,Lou Jianfeng¹²,Li Yafang³²,Zhou Feilong²,Yan Ziqin²,Lyu Xilin²,Zhao Yujun¹²⁴^ORCID

Affiliation:

1. University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China

2. State Key Laboratory of Drug Research and Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

3. Nano Science and Technology Institute, University of Science and Technology of China, Suzhou, Jiangsu 215123, China

4. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

Funder

Ministry of Science and Technology of the People's Republic of China

K. C. Wong Education Foundation

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00940

Reference117 articles.

1. MDM2, MDMX and p53 in oncogenesis and cancer therapy

2. p53: 800 million years of evolution and 40 years of discovery

3. The genetics of the p53 pathway, apoptosis and cancer therapy

4. Drugging the p53 pathway: understanding the route to clinical efficacy

5. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells;International Journal of Molecular Sciences;2024-08-30

2. Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors;Journal of Medicinal Chemistry;2024-08-26

3. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy;Cells;2024-06-29

4. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum^IV Complexes as Potent Antitumor Agents;Journal of Medicinal Chemistry;2024-05-22

5. Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme;Molecules;2024-05-19